Executive Leadership for a New Era of Biotech Operations & Quality
Martin Lush
​Executive Leader | Qualified Person | GxP AI Strategist | QMS Simplification Expert | Non-Executive Director
With over 40 years at the intersection of biotech operations, pharmaceutical quality, and regulatory compliance, I help organizations navigate complexity, modernize their systems, and build real resilience in an unpredictable world.
​
I’ve led from the shop floor to the boardroom—serving as Global VP in consulting, QA, manufacturing, operations, and supply chain across vaccines, biologics, and sterile injectables. I’m a Qualified Person under permanent provisions and a Non-Executive Director, with deep insight into both execution and oversight.
​
Today, I challenge outdated thinking and guide forward-looking companies to rewire their quality, compliance, and leadership systems for agility, speed, and impact.
What do I do?
GxP AI Implementation
Practical,
Compliant,
Game-Changing
-
Custom in-house AI education programs to demystify the tech and raise AI literacy across functions​
-
Real-world AI applications that improve compliance, reduce cost, and accelerate product release​
-
Smarter deviation/CAPA systems with predictive analytics and AI-enabled root cause support​
-
Strategies for integrating AI into your quality system—with built-in governance and validation frameworks
Quality Management Systems
From Bureaucracy to Competitive Advantage
-
QMS simplification for speed, flexibility, and leaner operations
-
Quality Maturity Model (QMM) expertise: assess, evolve, and lead
-
Human error prevention strategies grounded in behavioural science
-
Practical redesign of deviation and CAPA processes to prevent recurrence and drive learning
-
Crisis prevention: systems that absorb shock and adapt under pressure
Leadership Development
Built for High-Stakes Environments
-
One-to-one coaching for senior leaders under pressure
​
-
Embedding risk-based decision making and psychological resilience across teams
​
-
Culture transformation rooted in accountability, clarity, and future-readiness
Regulatory Compliance
Prepared for What's Next
-
Proactive FDA readiness, including strategy for the new regulatory realities of a Trump 2.0 era
​
-
Inspection prep that goes beyond checklists—focused on mindset, micro-behaviours, and risk-based thinking